<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samrat Pharmachem Limited has submitted a disclosure to BSE (Scrip Code: 530125) confirming that it does not qualify as a 'Large Corporate' under the SEBI circular dated November 26, 2018. The filing is a routine compliance requirement under Annexure A of SEBI's framework for large corporates, which typically applies to entities meeting certain market capitalisation or borrowing thresholds. The declaration was signed by Nishant Kankaria (Company Secretary & Compliance Officer) and Rajesh Mehta (Chief Financial Officer) on June 26, 2025. The company has effectively stated that it falls below the specified criteria and is therefore not subject to the additional borrowing and disclosure obligations that apply to large corporates.
This is a routine regulatory compliance filing with no material impact on shareholders or stock price. It simply confirms the company does not meet the SEBI threshold for 'Large Corporate' status, meaning it is not obligated to undertake mandatory incremental borrowing or ESG-related disclosures applicable to large corporates.